Szczudlik A, Słowik A, Tomik B
Kliniki Neurologii, Collegium Medicum U.J. w Krakowie.
Neurol Neurochir Pol. 1995 Sep-Oct;29(5):663-74.
The efficacy and tolerability of amitriptyline on the pathologic crying and other pseudobulbar signs were investigated in 22 consecutive patients diagnosed mostly as ALS. The occurrence and intensity of pathologic crying, dysarthria, dysphagia, jaw reflex and primitive reflexes (snout, palmo-mental and oral), were assessed before and after 3 and 6 weeks of amitriptyline treatment. The drug administered in low dose (30-100 mg, mean 64 +/- 17.6 mg) significantly decreased the frequency of pathologic crying in 17 patients after 3 weeks and in 20 patients after 6 weeks of treatment. There were no changes in the intensity of the other pseudobulbar signs. Only few mild and transient side effects were observed. The authors conclude, that amitriptyline is an effective treatment of pathologic crying in ALS patients.
对22例主要诊断为肌萎缩侧索硬化症（ALS）的连续患者，研究了阿米替林对病理性哭泣及其他假性延髓症状的疗效和耐受性。在阿米替林治疗3周和6周前后，评估病理性哭泣、构音障碍、吞咽困难、下颌反射及原始反射（噘嘴、掌颏和口反射）的发生情况和强度。以低剂量（30 - 100毫克，平均64±17.6毫克）给药，治疗3周后，17例患者病理性哭泣频率显著降低，治疗6周后，20例患者显著降低。其他假性延髓症状的强度无变化。仅观察到少数轻微和短暂的副作用。作者得出结论，阿米替林是治疗ALS患者病理性哭泣的有效药物。
